GleamWall
中文EN

SGP SpyGlass Pharma, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1778922 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.5%
ROA-31.1%
ROIC (approx.)-3,475.3%
Asset turnover—

Leverage & solvency

Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue———————
R&D expense$10.03M$10.94M$8.54M$7.71M$8.09M$7.33M$6.05M
SG&A expense$16.21M$11.03M$6.87M$5.92M$3.01M$1.96M$1.37M
Operating income-$26.25M-$21.97M-$15.41M-$13.63M-$11.10M-$9.30M-$7.42M
Pretax income-$24.25M-$19.86M-$13.82M-$12.55M-$9.82M-$8.68M-$8.82M
Income tax$0$0$0$0$0$0$0
Net income-$24.25M-$19.86M-$13.82M-$12.55M-$9.82M-$8.68M-$8.82M
EBITDA-$25.96M-$21.63M-$15.09M-$13.41M-$10.96M-$9.16M-$7.30M
EPS (basic)-0.73-0.59-0.69—-4.53-3.81-3.96
EPS (diluted)-0.73-0.59-0.69—-4.53-3.81-3.96
Weighted avg. shares (diluted)33.45M33.44M19.93M—2.17M2.28M2.23M
Balance sheet
Cash & equivalents$208.69M$223.14M$238.90M$96.36M$106.01M$127.23M$58.00M
Current assets$217.91M$236.46M$253.36M$108.77M———
PP&E, net$6.34M$4.79M$2.75M$2.34M———
Total assets$226.35M$243.43M$258.39M$115.87M———
Current liabilities$14.30M$9.44M$6.67M$8.58M———
Total liabilities$15.91M$11.07M$8.27M$10.17M———
Shareholders' equity$210.44M$232.36M$250.11M-$98.84M-$87.22M-$78.38M-$68.85M
Shares outstanding33.46M33.45M33.43M2.20M———
Cash flow statement
Operating cash flow-$16.02M-$14.84M-$13.54M-$9.34M-$8.84M-$6.33M-$8.20M
Capital expenditure$2.46M$1.93M$676,000$421,000$152,000$52,000$164,000
Free cash flow-$18.48M-$16.77M-$14.22M-$9.76M-$8.99M-$6.38M-$8.37M
Investing cash flow$1.54M-$933,000-$1.67M$574,000-$12.15M-$52,000-$164,000
Financing cash flow$27,000$13,000$157.75M-$888,000-$236,000$75.61M$50.10M
Depreciation & amortization$280,000$341,000$318,000$217,000$137,000$135,000$124,000
Stock-based compensation$2.30M$2.10M$1.68M$922,000$900,000$600,000$345,000
Share buybacks$0——$0$0——

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.